Short answer
10x Genomics, Inc. (TXG) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Board additions: Ansuman Satpathy and Joseph Gilliam appointed Class III directors through 2028 annual meeting.
10x Genomics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board additions: Ansuman Satpathy and Joseph Gilliam appointed Class III directors through 2028 annual meeting
- Satpathy adds genomics, immunology, AI-enabled drug discovery and biotech venture expertise
- Gilliam adds public-company operating, healthcare investment banking, accounting and audit committee experience
- Director compensation: $60,000 annual cash retainer, $400,000 initial RSU grant and $215,000 annual RSU grant
- Gilliam appointed Audit Committee Chair with additional $25,000 annual retainer, strengthening financial oversight
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other 10x Genomics, Inc. 8-K filings
Get the next TXG 8-K as it lands
Follow TXG for push alerts, or ask the research agent what this filing means.